The Rise of Luxury Car Theft and the AI-Powered Fight Against Antimicrobial Resistance

Turning AI Loose on Antimicrobial Resistance

On the other side of the technology spectrum, César de la Fuente, a researcher at the University of Pennsylvania, is demonstrating the extraordinary potential of artificial intelligence to solve problems that have stymied conventional approaches. His target is antimicrobial resistance, a crisis that the World Health Organization has identified as one of the top ten global public health threats.

Antimicrobial resistance occurs when bacteria, viruses, fungi, and parasites evolve to resist the drugs designed to kill them. The result is infections that become increasingly difficult or impossible to treat, turning routine medical procedures into life-threatening events. The pipeline of new antibiotics has slowed to a trickle in recent decades, as pharmaceutical companies have shifted investment toward more profitable drug categories.

De la Fuente's approach is radically different from traditional antibiotic discovery, which typically involves screening soil samples and microbial cultures for compounds with antimicrobial properties. Instead, his team uses machine learning algorithms to analyze vast databases of biological sequences, searching for peptides with potential antibiotic activity in places no one has thought to look before.

The AI systems can evaluate millions of candidate molecules in a fraction of the time it would take human researchers to screen even a small subset. More importantly, the algorithms can identify patterns and structural features associated with antimicrobial activity that might not be apparent to human analysts, opening up entirely new chemical spaces for drug discovery.

Unexpected Sources of New Antibiotics

One of the most remarkable aspects of de la Fuente's work is the range of sources he has explored. His team has identified potential antibiotic compounds in the genomes of extinct organisms, in the proteins of the human body itself, and in the vast troves of metagenomic data collected from environments around the world. The idea that the next breakthrough antibiotic might be hiding in the genetic code of a Neanderthal or in the chemistry of our own immune system challenges conventional assumptions about where new drugs come from.

The computational approach also accelerates the process of moving from discovery to development. Once a promising peptide is identified, the AI can help predict its behavior in biological systems, estimate its toxicity, and suggest modifications that might improve its effectiveness. This kind of in-silico optimization can shave years off the traditional drug development timeline, a critical advantage when resistant infections are killing an estimated 1.27 million people annually.

The Broader Lesson

Together, these two stories from The Download newsletter underscore a central theme of our technological moment: the tools we create are morally neutral, and their impact depends entirely on how they are deployed. Electronic devices that exploit vehicle security systems and AI algorithms that discover life-saving drugs are both products of the same culture of innovation. The challenge for society is to create incentives and guardrails that maximize the beneficial applications while minimizing the harmful ones.

The luxury car theft epidemic demands better security engineering, international law enforcement cooperation, and regulatory frameworks that hold technology sellers accountable. The antimicrobial resistance crisis demands sustained investment in AI-driven drug discovery, reformed incentive structures for pharmaceutical development, and global coordination to ensure new antibiotics reach the patients who need them most. In both cases, technology alone is not enough. It must be paired with the institutional capacity to direct it toward constructive ends.

This article is based on reporting by MIT Technology Review. Read the original article.